

---

## Xspray Pharma Q3 2024 - Raising cash and anticipates H1 2025 launch of Dasynoc

Redeye updates its valuation model following Xspray's announcement of SEK235m in financing and the company's Q3 report, which reaffirmed the anticipated timeline for Dasynoc and expected Q2 2025 NDA submission for XS003.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. [www.redeye.se/](http://www.redeye.se/)

### Attachments

---

[Xspray Pharma Q3 2024 - Raising cash and anticipates H1 2025 launch of Dasynoc](#)